Why the study?
Does carvedilol added to standard therapy reduce clinical progression in patients with mildly symptomatic, well-compensated heart failure?
Does carvedilol added to standard therapy reduce clinical progression in patients with mildly symptomatic, well-compensated heart failure?
Carvedilol added to standard therapy including an ACE inhibitor is effective at reducing clinical progression in patients with mildly symptomatic heart failure.
Supports carvedilol addition to ACE inhibitor therapy in mild HF; extends beta-blocker benefits to less symptomatic patients.
Carvedilol, when added to standard therapy, including an ACE inhibitor, reduces clinical progression in patients who are only mildly symptomatic with well-compensated heart failure.
No takes yet. Share an insight, caveat, or question.
Colucci et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: